{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:51:53Z","timestamp":1760550713737},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Rising rates of multidrug-resistant organisms has necessitated the development of novel antimicrobials. In this review, we will highlight agents that have recently received licensure and those that are in clinical development.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In recent years, development of novel antimicrobial agents has accelerated. Although most studies have targeted the adult population, studies in pediatric patients are underway. Adequately powered clinical trials are needed to establish the safety and role of these new drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The recent development of novel antimicrobials to combat multidrug-resistant organisms is encouraging; however, more studies in the pediatric population are needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000713","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T21:02:55Z","timestamp":1543611775000},"page":"135-143","source":"Crossref","is-referenced-by-count":3,"title":["Advances in pediatric antimicrobial agents development"],"prefix":"10.1097","volume":"31","author":[{"given":"James B.","family":"Wood","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauryn B.","family":"Cravens","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Buddy","family":"Creech","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"e0189621","DOI":"10.1371\/journal.pone.0189621","article-title":"Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis","volume":"12","author":"Founou","year":"2017","journal-title":"PLoS One"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/jpids\/piw093","article-title":"Incidence and outcomes of infections caused by multidrug-resistant Enterobacteriaceae in children","volume":"7","author":"Meropol","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40121-016-0144-8","article-title":"Use of Ceftaroline Fosamil in children: review of current knowledge and its application","volume":"6","author":"Yim","year":"2017","journal-title":"Infect Dis Ther"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijantimicag.2008.12.005","article-title":"Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia","volume":"33","author":"Morrissey","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.pcl.2017.08.005","article-title":"New antimicrobial agents for the treatment of Staphylococcal infections in children","volume":"64","author":"Sharma","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1128\/AAC.04965-14","article-title":"Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37","volume":"59","author":"Sakoulas","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20230918","first-page":"476","article-title":"Ceftaroline Fosamil use in 2 pediatric patients with invasive methicillin-resistant Staphylococcus aureus infections","volume":"20","author":"Williams","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/INF.0000000000001159","article-title":"A Randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone","volume":"35","author":"Cannavino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","article-title":"A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection","volume":"35","author":"Korczowski","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1093\/jpids\/piw002","article-title":"Agranulocytosis in a pediatric patient treated with ceftaroline","volume":"5","author":"Shirley","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2146\/ajhp130482","article-title":"Tedizolid: a new oxazolidinone antimicrobial","volume":"71","author":"Kisgen","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, noninferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/INF.0000000000001096","article-title":"Pharmacokinetics, safety, tolerability of single oral or intravenous administration of 200\u200amg tedizolid phosphate in adolescents","volume":"35","author":"Bradley","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/QCO.0000000000000439","article-title":"The role of tedizolid in skin and soft tissue infections","volume":"31","author":"Bouza","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijantimicag.2016.11.032","article-title":"Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report","volume":"49","author":"Matin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1097\/MJT.0000000000000534","article-title":"Characterization of neurologic and ophthalmologic safety of oral administration of tedizolid for up to 21 days in healthy volunteers","volume":"24","author":"Fang","year":"2017","journal-title":"Am J Ther"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1128\/AAC.00431-13","article-title":"In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions","volume":"57","author":"Flanagan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20230918","article-title":"Thrombocytopenia with tedizolid and linezolid","volume":"62","author":"Lee","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s10096-016-2756-z","article-title":"Dalbavancin for the treatment of paediatric infectious diseases","volume":"35","author":"Esposito","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram positive infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect Dis Ther"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/fmb-2017-0310","article-title":"Oritavancin: an update","volume":"13","author":"Fl\u00fch","year":"2018","journal-title":"Future Microbiol"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/INF.0000000000001538","article-title":"Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age","volume":"36","author":"Gonzalez","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/INF.0000000000000646","article-title":"Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age","volume":"34","author":"Bradley","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study","volume":"50","author":"Stryjewski","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4140\/TCP.n.2016.86","article-title":"Oritavancin: a novel lipoglycopeptide","volume":"31","author":"Mattox","year":"2016","journal-title":"Consult Pharm"},{"key":"R31-20230918","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01919-17","article-title":"Single intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: summary of safety analysis from the phase 3 SOLO studies","volume":"62","author":"Corey","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1128\/AAC.00358-13","article-title":"Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in","volume":"57","author":"Paukner","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jac\/dks001","article-title":"Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)","volume":"67","author":"Sader","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R35-20230918","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00692-18","article-title":"Population pharmacokinetics and safety of solithromycin following intravenous and oral administration in infants, children, and adolescents","volume":"62","author":"Gonzalez","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, noninferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R37-20230918","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy003","article-title":"An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria","volume":"5","author":"Huang","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R38-20230918","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02580-17","article-title":"A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens (REVIVE-2 Study)","volume":"62","author":"Holland","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R40-20230918","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/INF.0000000000001859","article-title":"Ceftazidime-avibactam antimicrobial activity and spectrum when tested against gram-negative organisms from pediatric patients: results from the INFORM Surveillance Program (United States)","volume":"37","author":"Sader","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R42-20230918","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 noninferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R44-20230918","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1128\/AAC.00862-16","article-title":"Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients","volume":"60","author":"Bradley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-20230918","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/phar.1609","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"35","author":"Cho","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R46-20230918","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/INF.0000000000002170","article-title":"Pharmacokinetics and safety of single intravenous doses of ceftolozane\/tazobactam in children with proven or suspected gram-negative infection","volume":"37","author":"Bradley","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R48-20230918","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"R49-20230918","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/MOP.0b013e32835c1fc2","article-title":"Newer antifungal agents","volume":"25","author":"Larru","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"R50-20230918","article-title":"New horizons in antifungal therapy","volume":"2","author":"Pianalto","year":"2016","journal-title":"J Fungi (Basel)"},{"key":"R51-20230918","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bcp.13401","article-title":"Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children","volume":"84","author":"Allegra","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"(Suppl 2)","key":"R52-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2012.03772.x","article-title":"Cordonnier C Antifungal prophylaxis in haematology patients: the role of voriconazole","volume":"18","author":"Hicheri","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R53-20230918","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R54-20230918","first-page":"17","article-title":"Voriconazole monitoring in children with invasive fungal infections","volume":"20","author":"Tucker","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R55-20230918","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkw056","article-title":"Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre","volume":"71","author":"Boast","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R56-20230918","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R57-20230918","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"R58-20230918","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients","volume":"17","author":"Winston","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R59-20230918","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2334-12-263","article-title":"Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation","volume":"12","author":"D\u00f6ring","year":"2012","journal-title":"BMC Infect Dis"},{"key":"R60-20230918","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/14787210.2018.1490177","article-title":"Posaconazole in immunocompromised pediatric patients","volume":"16","author":"Vicenzi","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R61-20230918","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R62-20230918","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R63-20230918","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/j.bbmt.2016.12.150","article-title":"Intravenous posaconazole is safe and effective in pediatric HSCT patients","volume":"23","author":"Teusink-Cross","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R64-20230918","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R65-20230918","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","article-title":"Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R66-20230918","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, noninferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"R67-20230918","doi-asserted-by":"crossref","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R68-20230918","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin antifungal drugs in fungal infections: a comparison","volume":"71","author":"Chen","year":"2011","journal-title":"Drugs"},{"key":"R69-20230918","article-title":"Efficacy and safety of echinocandins for the treatment of invasive Candidiasis in children: a meta-analysis","author":"Tsekoura","year":"2018","journal-title":"Pediatr Infect Dis J"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201902000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:20:20Z","timestamp":1695003620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201902000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000713","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}